AZD3293: Pharmacokinetic and pharmacodynamic effects in healthy subjects and patients with Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 55, Issue 3, 2017, Pages 1039-1053

  Cebers, Gvido ^a,e   Alexander, Robert C ^a,f   Haeberlein, Samantha Budd ^a,g   Han, David ^b   Goldwater, Ronald ^c   Ereshefsky, Larry ^b   Olsson, Tina ^a,g   Ye, Naidong ^a,h   Rosen, Laura ^a,i   Russell, Muir ^a   Maltby, Justine ^a   Eketjäll, Susanna ^d   Kugler, Alan R ^a,j  

^a ASTRAZENECA   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

^c HARBOR HOSPITAL   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Independent Consultant   (United States)

^f PFIZER INC   (United States)

^g BIOGEN   (United States)

^h Millendo Therapeutics US   (United States)

ⁱ Flex Pharma Inc   (United States)

^j Clinical Pharmacology   (United States)

more..

Author keywords

Amyloid beta peptides; AZD3293; BACE1 protein human; cerebrospinal fluid proteins; early onset Alzheimer's disease; pharmacodynamics; pharmacokinetics; Phase I clinical trials

Indexed keywords

4 METHOXY 5'' METHYL 6'[5 (PROP 1 YN 1 YL)PYRIDIN 3 YL] 3'H DISPIRO[CYCLOHEXANE 1,2' INDENE 1',2'' IMIDAZOL] 4'' AMINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; NOOTROPIC AGENT; UNCLASSIFIED DRUG; 4-METHOXY-5'-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2'-IMIDAZOL)-4'-AMINE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IMIDAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PEPTIDE FRAGMENT; SPIRO COMPOUND;

ABDOMINAL DISTENSION; ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG CONCENTRATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; DYSURIA; FEMALE; FLATULENCE; FLUSHING; FOOD; FOOD DRUG INTERACTION; FOREIGN BODY; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY URGENCY; VISUAL ACUITY; ADOLESCENT; AGE; AGED; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; NEUROLOGIC EXAMINATION; NORMAL HUMAN; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FOOD; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PEPTIDE FRAGMENTS; SPIRO COMPOUNDS; TIME FACTORS; YOUNG ADULT;

EID: 85005978119     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160701     Document Type: Article

References (42)

1. Dementia Fact sheet number 362 Geneva: World Health Organization, March 2015, WHO, http://www.who.int/med iacentre/factsheets/fs362/en/ Accessed September 6, 2016.
2. Wortmann M. (2012) Dementia: A global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4, 40.
3. Cole SL, Vassar R. (2007) The Alzheimer?s disease betasecretase enzyme, BACE1. Mol Neurodegener 2, 22.
4. Karran E, Mercken M, De Strooper B. (2011) The amyloid cascade hypothesis for Alzheimer?s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov 10, 698-712.
5. Menting KW, Claassen JA. (2014) beta-secretase inhibitor; a promising novel therapeutic drug in Alzheimer?s disease. Front Aging Neurosci 6, 165.
6. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, Lichtenthaler SF. (2014) Function, therapeutic potential and cell biology ofBACE proteases: Current status and future prospects. J Neurochem 130, 4-28.
7. Hardy J, Selkoe DJ. (2002) The amyloid hypothesis of Alzheimer?s disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
8. Selkoe DJ. (1991) The molecular pathology of Alzheimer?s disease. Neuron 6, 487-498.
9. Yan R, Vassar R. (2014) Targeting the beta secretase BACE1 for Alzheimer?s disease therapy. Lancet Neurol 13, 319-329.
10. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer?s disease. Nature 349, 704-706.
11. Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, Hofman A, Van Broeckhoven C. (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-Amyloid precursor protein gene. Nat Genet 1, 218-221.
12. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. (1992) A pathogenic mutation for probable Alzheimer?s disease in the APP gene at the Nterminus of beta-Amyloid. Nat Genet 1, 345-347.
13. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. (1992) Mutation of the beta-Amyloid precursor protein in familial Alzheimer?s disease increases beta-protein production. Nature 360, 672-674.
14. Cai XD, Golde TE, Younkin SG. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259, 514-516.
15. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor. (beta APP717) mutants. Science 264, 1336-1340.
16. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. (2001) Age-dependent changes in brain, CSF, and plasma amyloid. (beta) protein in the Tg2576 transgenic mouse model of Alzheimer?s disease. J Neurosci 21, 372-381.
17. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L. (2001)BACEknockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer?s disease therapeutics. Hum Mol Genet 10, 1317-1324.
18. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC. (2005) BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 25, 11693-11709.
19. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S. (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 282, 26326-26334.
20. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. (2012) Amutation in APP protects against Alzheimer?s disease and age-related cognitive decline. Nature 488, 96-99.
21. Butini S, Brogi S, Novellino E, Campiani G, Ghosh AK, Brindisi M, Gemma S. (2013) The structural evolution of beta-secretase inhibitors: A focus on the development of small-molecule inhibitors. Curr Top Med Chem 13, 1787-1807.
22. Oehlrich D, Prokopcova H, Gijsen HJ. (2014) The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett 24, 2033-2045.
23. Vassar R. (2014) BACE1 inhibitor drugs in clinical trials for Alzheimer?s disease. Alzheimers Res Ther 6, 89.
24. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE. (2011) Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31, 16507-16516.
25. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martenyi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ. (2015) The potent BACE1 inhibitor LY2886721 elicits robust central Abeta pharmacodynamic responses in mice, dogs, and humans. J Neurosci 35, 1199-1210.
26. Forman M, Kleijn HJ, Dockendorf M, Palcza J, Tseng J, Canales C. (2013) The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-Amyloid in patients with mild-To-moderate Alzheimer?s disease. Alzheimers Dement 9, P139.
27. Lai R, Albala B, Kaplow JM, Aluri J, Yen M, Satlin A. (2012) First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma betaamyloid levels after single dosing. Alzheimers Dement 8, P96.
28. Timmers M, Van Broeck B, Slemmon J, De Waepenaert K, Russu A, Bogert J. (2015) Profiling the dynamics of CSF and plasma Abeta reduction with JNJ-54861911, an oral BACE inhibitor. Neurodegener Dis 15, 310.
29. Yan R. (2016) Stepping closer to treating Alzheimer?s disease patients with BACE1 inhibitor drugs. Transl Neurodegener 5, 13.
30. Eketjall S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Falting J, Haeberlein SB, Kugler AR, Alexander RC, Cebers G. (2016) AZD3293:Anovel, orally active BACE1 inhibitor with high potency and permeability and markedly slow offrate kinetics. J Alzheimers Dis 50, 1109-1123.
31. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. (2011) The diagnosis of dementia due to Alzheimer?s disease: Recommendations from the National Institute on Aging-Alzheimer?s Association workgroups on diagnostic guidelines for Alzheimer?s disease. Alzheimers Dement 7, 263-269.
32. Folstein MF, Folstein SE, McHugh PR. (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
33. Columbia-Suicide Severity Rating Scale. (Japanese Version), Columbia University Medical Center, http://www. cssrs.columbia.edu, Accessed September 6, 2016.
34. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. (1998) The Mini-International Neuropsychiatric Interview. (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20), 22-33; quiz 34-57.
35. Bell J, O?Neill B, Brodney M, Hajos-Korcsok E, Lu Y, Riddell D. (2013) A two-part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta-Amyloid in a first-in-human study. Alzheimers Dement 9, P287.
36. Quartino A, Huledal G, Sparve E, Luttgen M, Bueters T, Karlsson P, Olsson T, Paraskos J, Maltby J, Claeson-Bohnstedt K, Lee CM, Alexander R, Falting J, Paulsson B. (2014) Population pharmacokinetic and pharmacodynamic analysis of plasma Abeta40 and Abeta42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers. Clin Pharmacol Drug Dev 3, 396-405.
37. BACE Inhibitor BI 1181181 Voluntarily Put on Temporary Clinical Hold for Safety Evaluation, Vitae Pharmaceuticals, http://ir.vitaepharma.com/phoenix.zhtml?c=219654&p=ir ol-newsArticle&ID=2020814, Accessed September 6, 2016.
38. MacLeod R, Hillert EK, Cameron RT, Baillie GS. (2015) The role and therapeutic targeting of-,-And-secretase in Alzheimer?s disease. Future Sci 1, FSO11.
39. Eketjall S, Janson J, Jeppsson F, Svanhagen A, Kolmodin K, Gustavsson S, Radesater AC, Eliason K, Briem S, Appelkvist P, Niva C, Berg AL, Karlstrom S, Swahn BM, Falting J. (2013) AZ-4217: A high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci 33, 10075-10084.
40. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C. (2015) Delayed-start analysis: Mild Alzheimer?s disease patients in solanezumab trials, 3.5 years. Alzheimers Dement 1, 111-121.
41. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. (2014) Phase 3 trials of solanezumab for mild-To-moderate Alzheimer?s disease. N Engl J Med 370, 311-321.
42. Georgievska B, Gustavsson S, Lundkvist J, Neelissen J, Eketjall S, Ramberg V, Bueters T, Agerman K, Jureus A, Svensson S, Berg S, Falting J, Lendahl U. (2015) Revisiting the peripheral sink hypothesis: Inhibiting BACE1 activity in the periphery does not alter beta-Amyloid levels in the CNS. J Neurochem 132, 477-486.